[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

USRE39743E1 - 2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use - Google Patents

2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use Download PDF

Info

Publication number
USRE39743E1
USRE39743E1 US10/302,324 US30232402A USRE39743E US RE39743 E1 USRE39743 E1 US RE39743E1 US 30232402 A US30232402 A US 30232402A US RE39743 E USRE39743 E US RE39743E
Authority
US
United States
Prior art keywords
compound
formula
methyl
hydrogen
hal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/302,324
Inventor
Constantin Agouridas
Francois Bretin
Alexis Denis
Claude Fromentin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9812937A external-priority patent/FR2784682B1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to US10/302,324 priority Critical patent/USRE39743E1/en
Application granted granted Critical
Publication of USRE39743E1 publication Critical patent/USRE39743E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • novel products of the invention are compounds selected from the group consisting of a compound of the formula wherein A is nitrogen or N ⁇ O, R 1 and R 2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 18 carbons atoms, R is selected from the group consisting of hydrogen and —(CH 2 ) m OB, Hal is halogen, m and n are individually an integer from 1 to 8, B is hydrogen or Ar is a mono- or polycyclic aryl or heteroaryl, Z is hydrogen or acyl of an organic carboxylic acid of up to 18 carbon atoms and its non-toxic, pharmaceutically acceptable acid addition salts.
  • acids for the acid addition salts are acetic acid, propionic acid, trifluoroacetic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and particularly stearic acid, ethylsuccinic acid or laurylsulfonic acid.
  • alkyl examples include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, terbutyl, decyl and dodecyl.
  • aryl examples are phenyl or naphthyl and examples of heteroaryl are thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isopyrazolyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl and also indolyl, benzofurannyl, benzothiazyl and quinolinyl.
  • substituents are at least one of hydroxyl, halogen, —NO 2 , —C ⁇ N, alkyl, alkenyl or alkynyl, O-alkyl, O-alkenyl or O-alkynyl, S-alkyl, S-alkenyl or S-alkynyl and N-alkyl, N-alkenyl or N-alkynyl of up to 12 carbon atoms optionally substituted by at least one halogen, R a and R b individually being hydrogen or alkyl of up to 12 carbon atoms, R 3 being alkyl of up to 12 carbon atoms, or an optionally substituted aryl or heteroaryl radical, carbocyclic aryl, O-aryl or S-aryl, or heterocyclic aryl, O-aryl or S-aryl with 5 or 6 members comprising at least one heteroatom, optionally substituted by one or more of the above substituents.
  • Hal is halogen, preferably fluorine or chlorine. When one of the substituents is halogen, it is preferably fluorine, chlorine or bromine.
  • R 1 and R 2 are hydrogen, those wherein A is nitrogen, those wherein Hal is fluorine, those wherein R is hydrogen and those wherein R is —CH 2 OH.
  • the process for the preparation of a compound of formula I comprises reacting a compound of the formula wherein Hal is halogen and OM is a protected hydroxyl with a compound of the formula wherein m is an integer from 1 to 8 to obtain a compound of the formula deprotecting the 2′-hydroxyl to obtain a compound of the formula reacting the latter with a debenzylating agent to obtain a compound of the formula reacting the latter with a cyclization agent to form a compound of the formula wherein R is —(CH 2 ) m —OH and optionally subjecting the latter to aralkylating or acylating agent to obtain a compound of claim 1 wherein B is —(CH 2 ) n —Ar or
  • the process comprises reacting a compound of the formula wherein —OZ is —OH or a protected hydroxyl with a fluorination agent to obtain a compound of the formula which is then reacted with carboxyldiimidazole to obtain the compound of formula II.
  • a fluorination agent to obtain a compound of the formula which is then reacted with carboxyldiimidazole to obtain the compound of formula II.
  • Other products can be prepared in an analogous manner.
  • OZ is acetyl or benzoyl and the protected hydroxyl can be released by methanolysis.
  • the debenzylation may be effected by hydrogenation such as with palladium on carbon in the presence of ammonium formate at methanol reflux and cyclization may be effected at ethanol reflux in the presence of acetic acid.
  • the acylation or arylation can be carried out by standard procedures.
  • the preferred halogenation agent is bisphenyl sulfonylimide of the Formula
  • novel antibiotic compositions of the invention are comprised of an antibiotically effective amount of a compound of formula I and its non-toxic, pharmaceutically acceptable acid addition salts and an inert pharmaceutical carrier.
  • the compositions may be in the form of plain or sugar-coated tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels.
  • Examples of the pharmaceutical carriers are talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents and preservatives.
  • compositions can also be present in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example, apyrogenic sterile water.
  • compositions have a very good antibiotic activity on gram ⁇ bacteria such as staphylococcis, streptococcis, pneumococcis and therefore are useful in the treatment of germ-sensitive infections and particularly in that of staphylococcia such as staphylococcal septicaemias, malignant staphylococcia of the face or skin, pyodermitis, septic or suppurant wounds, boils, anthrax, phlegmons, erysipelas and acne, staphylococcia such as primitive or post-influenzal acute angina, bronchopneumonia, pulmonary suppuration, streptococcia such as acute angina, otitis, sinusitis, scarlatina, pneumococcia such as pneumonia, bronchitis; brucellosis, diphtheria, gonococcal infection.
  • staphylococcia such as staphylococcal septicaemias, malignant staphylococc
  • compositions are also active against infections caused by germs such as Haemophilus influenzae, Rickettsia, Mycoplasma pneumoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma, or germs of the Mycobacterium genus.
  • the method of treating bacterial infections in warm-blooded animals comprises administering to a warm-blooded animal an antibiotically effective amount of a compound of formula I or its acid addition salt.
  • the compounds can be administered buccally, rectally, parenterally or by topical application on the skin and mucous membranes, but the preferred administration route is the buccal route.
  • the usual effective daily dose is 2 to 15 mg/kg depending on the method of administration and the active compound.
  • the mixture was stirred for 5 days during which twice 0.2 eq of 3-pyrazolamine and twice 0.2 eq of hexamethylsilylamine were added followed by drying and taking up in methylene chloride. 30 ml of a solution of sodium dihydrogen phosphate were added and the mixture was stirred for 15 minutes followed by decanting. The aqueous phase was extracted with methylene chloride and the chloromethylenic phases were combined, dried, filtered and evaporated to obtain 1.2259 g of the desired product.
  • a solution of 1.1003 g of the product of Stage A and 11 ml of THF was cooled to ⁇ 10° C. and 1.86 ml of potassium terbutylate in THF were added. The mixture was stirred for 5 minutes and 0.588 g of were added. The mixture was stirred for 10 minutes at ⁇ 10° C. and the reaction medium was allowed to return to ambient temperature. The mixture was stirred at ambient temperature for 1 hour 30 minutes followed by filtration. The precipitate was rinsed with ethyl acetate and the filtrate was concentrated and taken up to 10 ml of ethyl acetate, 10 ml of water and 5 ml of a 20% aqueous solution of ammonium hydroxide. The mixture was stirred for 10 minutes followed by decanting, washing with water and extracting with ethyl acetate. The organic phases were combined, dried, filtered and evaporated to dryness to obtain 1.1067 g of the desired product.
  • a mixture of 3.08 g of the product of Stage A, 340 mg of imidazole, 32 ml of anhydrous THF and 1.06 ml of hexamethyl-disilylazane was stirred at ambient temperature for 4 days.
  • the reaction medium was then evaporated to dryness and the residue was taken up in a mixture of 60 ml of methylene chloride and 60 ml of a 0.5 M aqueous solution of sodium acid phosphate.
  • the mixture was stirred for 15 minutes followed by decanting, extracting with is methylene chloride, drying and evaporating to dryness to obtain 3.345 g of the desired product.
  • a series of tubes were prepared in which the same quantity of nutritive sterile medium was distributed. Increasing quantities of the product to be studied were distributed into each tube and then each tube was seeded with a bacterial strain. After incubation for twenty-four hours in an oven at 37° C., the growth inhibition was evaluated by transillumination, which allowed the minimal inhibitory concentrations (M.I.C.) to be determined, expressed in micrograms/ml. The following results were obtained: (reading after 24 hours)
  • Example 1 showed a useful activity on the following Gram bacterial strains: Haemophillus Influenzae 351HT3, 351CB12 and 351CA1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel compounds of the formula
Figure USRE039743-20070724-C00001
wherein the substituents are defined as in the application having antibiotic properties.

Description

SUMMARY OF THE INVENTION
Novel 2-halogenated derivatives of 5-0-desosaminyl-erythronolide A and their use.
OBJECTS OF THE INVENTION
It is an object of the invention to provide the novel compounds of formula I and their acid addition salts and a process for their preparation.
It is another object of the invention to provide novel antibiotic compositions and a method of treating bacterial infections in warm-blooded animals.
These and other objects and advantages of the invention will become obvious from the following detailed description.
THE INVENTION
The novel products of the invention are compounds selected from the group consisting of a compound of the formula
Figure USRE039743-20070724-C00002
wherein A is nitrogen or N→O, R1 and R2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 18 carbons atoms, R is selected from the group consisting of hydrogen and —(CH2)mOB, Hal is halogen, m and n are individually an integer from 1 to 8, B is hydrogen or
Figure USRE039743-20070724-C00003
Ar is a mono- or polycyclic aryl or heteroaryl, Z is hydrogen or acyl of an organic carboxylic acid of up to 18 carbon atoms and its non-toxic, pharmaceutically acceptable acid addition salts.
Examples of acids for the acid addition salts are acetic acid, propionic acid, trifluoroacetic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and particularly stearic acid, ethylsuccinic acid or laurylsulfonic acid.
Examples of alkyl are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, terbutyl, decyl and dodecyl.
Examples of aryl are phenyl or naphthyl and examples of heteroaryl are thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isopyrazolyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl and also indolyl, benzofurannyl, benzothiazyl and quinolinyl.
Examples of substituents are at least one of hydroxyl, halogen, —NO2, —C≡N, alkyl, alkenyl or alkynyl, O-alkyl, O-alkenyl or O-alkynyl, S-alkyl, S-alkenyl or S-alkynyl and N-alkyl, N-alkenyl or N-alkynyl of up to 12 carbon atoms optionally substituted by at least one halogen,
Figure USRE039743-20070724-C00004
Ra and Rb individually being hydrogen or alkyl of up to 12 carbon atoms,
Figure USRE039743-20070724-C00005
R3 being alkyl of up to 12 carbon atoms, or an optionally substituted aryl or heteroaryl radical, carbocyclic aryl, O-aryl or S-aryl, or heterocyclic aryl, O-aryl or S-aryl with 5 or 6 members comprising at least one heteroatom, optionally substituted by one or more of the above substituents.
Hal is halogen, preferably fluorine or chlorine. When one of the substituents is halogen, it is preferably fluorine, chlorine or bromine.
Among the preferred compounds of formula I are those wherein R1 and R2 are hydrogen, those wherein A is nitrogen, those wherein Hal is fluorine, those wherein R is hydrogen and those wherein R is —CH2OH.
The process for the preparation of a compound of formula I comprises reacting a compound of the formula
Figure USRE039743-20070724-C00006
wherein Hal is halogen and OM is a protected hydroxyl with a compound of the formula
Figure USRE039743-20070724-C00007
wherein m is an integer from 1 to 8 to obtain a compound of the formula
Figure USRE039743-20070724-C00008
deprotecting the 2′-hydroxyl to obtain a compound of the formula
Figure USRE039743-20070724-C00009
reacting the latter with a debenzylating agent to obtain a compound of the formula
Figure USRE039743-20070724-C00010
reacting the latter with a cyclization agent to form a compound of the formula
Figure USRE039743-20070724-C00011
wherein R is —(CH2)m—OH and optionally subjecting the latter to aralkylating or acylating agent to obtain a compound of claim 1 wherein B is —(CH2)n—Ar or
Figure USRE039743-20070724-C00012
The starting compounds of formula II are described in French patent application 98-04366 filed Apr. 8, 1998 and a detailed description of the process for the preparation of compounds of formula II wherein Hal is fluorine is described herein.
The process comprises reacting a compound of the formula
Figure USRE039743-20070724-C00013
wherein —OZ is —OH or a protected hydroxyl with a fluorination agent to obtain a compound of the formula
Figure USRE039743-20070724-C00014
which is then reacted with carboxyldiimidazole to obtain the compound of formula II. Other products can be prepared in an analogous manner.
Preferably, OZ is acetyl or benzoyl and the protected hydroxyl can be released by methanolysis. The debenzylation may be effected by hydrogenation such as with palladium on carbon in the presence of ammonium formate at methanol reflux and cyclization may be effected at ethanol reflux in the presence of acetic acid. The acylation or arylation can be carried out by standard procedures.
The compound S of formulae IV, V and VI are novel and are part of the invention.
In a variation of the process to prepare the compounds of formula I, a compound of the formula
Figure USRE039743-20070724-C00015
wherein A, R, R1 and R2 are defined as above and —OM is a protected hydroxyl is reacted with a halogenation agent to obtain a compound of the formula
Figure USRE039743-20070724-C00016
which is optionally reacted with an agent to free the 2′-hydroxyl to obtain the compound of formula I wherein in Z is hydrogen and optionally with an esterification agent to obtain the 2′-acylated compound or with an acid to form the acid addition salt.
The preferred halogenation agent is bisphenyl sulfonylimide of the Formula
Figure USRE039743-20070724-C00017
The novel antibiotic compositions of the invention are comprised of an antibiotically effective amount of a compound of formula I and its non-toxic, pharmaceutically acceptable acid addition salts and an inert pharmaceutical carrier. The compositions may be in the form of plain or sugar-coated tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels.
Examples of the pharmaceutical carriers are talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents and preservatives.
The compositions can also be present in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example, apyrogenic sterile water.
The compositions have a very good antibiotic activity on gram ⊕ bacteria such as staphylococcis, streptococcis, pneumococcis and therefore are useful in the treatment of germ-sensitive infections and particularly in that of staphylococcia such as staphylococcal septicaemias, malignant staphylococcia of the face or skin, pyodermitis, septic or suppurant wounds, boils, anthrax, phlegmons, erysipelas and acne, staphylococcia such as primitive or post-influenzal acute angina, bronchopneumonia, pulmonary suppuration, streptococcia such as acute angina, otitis, sinusitis, scarlatina, pneumococcia such as pneumonia, bronchitis; brucellosis, diphtheria, gonococcal infection.
The compositions are also active against infections caused by germs such as Haemophilus influenzae, Rickettsia, Mycoplasma pneumoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma, or germs of the Mycobacterium genus.
The method of treating bacterial infections in warm-blooded animals comprises administering to a warm-blooded animal an antibiotically effective amount of a compound of formula I or its acid addition salt. The compounds can be administered buccally, rectally, parenterally or by topical application on the skin and mucous membranes, but the preferred administration route is the buccal route. The usual effective daily dose is 2 to 15 mg/kg depending on the method of administration and the active compound.
In the following examples, there are described various preferred embodiments to illustrate the invention. However, it is to be understood that the invention is not intended to be limited to the specific embodiments.
EXAMPLE 1 [3as-(3aR*,4S*,7R*,9S*,10S*,11S*,13S*,15S*,15aS)*]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethyl-amino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(9H)-trione
  • Stage A: [3aS-(3aR*,4S*,7S*,9S*,10S*,11S*,13S*,15S*,15aS*)]-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethyl-amino)-2-0-(trimethylsilyl)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-oxazole-2,6,8(7H, 9H)-trione
A mixture of 0.9835 g of [3aS-(3aR*,4S*,7S*,9S*,10S*,11S*,13S*,15S*,15aS*)]-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethyl-amino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione (EP 0638585) and 9.8 ml of THF were stirred for 5 minutes and then 105 mg of imidazole and 0.327 ml of hexamethylsilylamine [(CH3)3Si]2NH were added. The mixture was stirred for 5 days during which twice 0.2 eq of 3-pyrazolamine and twice 0.2 eq of hexamethylsilylamine were added followed by drying and taking up in methylene chloride. 30 ml of a solution of sodium dihydrogen phosphate were added and the mixture was stirred for 15 minutes followed by decanting. The aqueous phase was extracted with methylene chloride and the chloromethylenic phases were combined, dried, filtered and evaporated to obtain 1.2259 g of the desired product.
  • Stage B: [3aS-(3aR*,4S*,7S*,9S*,10S*,11S*,13S*,15S*,15aS*)]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-2-0-(trimethylsilyl)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetra-decino[4,3-d]oxazole-2,6,8(7H,9H)-trione
A solution of 1.1003 g of the product of Stage A and 11 ml of THF was cooled to −10° C. and 1.86 ml of potassium terbutylate in THF were added. The mixture was stirred for 5 minutes and 0.588 g of
Figure USRE039743-20070724-C00018
were added. The mixture was stirred for 10 minutes at −10° C. and the reaction medium was allowed to return to ambient temperature. The mixture was stirred at ambient temperature for 1 hour 30 minutes followed by filtration. The precipitate was rinsed with ethyl acetate and the filtrate was concentrated and taken up to 10 ml of ethyl acetate, 10 ml of water and 5 ml of a 20% aqueous solution of ammonium hydroxide. The mixture was stirred for 10 minutes followed by decanting, washing with water and extracting with ethyl acetate. The organic phases were combined, dried, filtered and evaporated to dryness to obtain 1.1067 g of the desired product.
  • Stage C: [3aS-(3aR*,4S*,7S*,9S*,10S*,11S*,13S*,15S*,15aS*)]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(9H)-trione
1.13 ml of a solution of tetrabutylammonium fluoride in THF were added to a solution of 0.55 g of the product of Stage A and 5.5 ml of THF and the mixture was stirred for 4 hours 30 minutes. The solvent was evaporated off and the residue was taken up in 5 ml of ethyl acetate, 5 ml of water and 2 ml of a 20% solution of ammonium hydroxide. The mixture was stirred for 15 minutes followed by decanting. The aqueous phase was extracted with ethyl acetate followed by washing with water. The aqueous phase was re-extracted and the organic phases were combined, dried, filtered and evaporated to dryness to obtain 0.4134 g of the desired product.
EXAMPLE 2 (3aS,4R,7S,9R,10R,11R,13R,15R,15aR,18S)-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-(hydroxymethyl)-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H, 9H)-trione
  • State A: 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-0-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-fluoro-6-0-methyl-3-oxo-12,11-[oxycarbonyl[[(2R)-1-hydroxy-3-[(phenylmethyl)amino]-2-propyl]imino]-2′-acetoxy
6.7 g of the product of Preparation I were introduced into a solution of 8.33 g of (R)-2-amino-3-[(phenyl-methyl)amino]-1-propanol, 67 ml of acetonitrile and 6.7 ml of water and after the is reaction mixture was taken to 55°, it was maintained at this temperature for 21 hours. The reaction mixture was then poured into a water-ethyl acetate mixture followed by decanting, extracting with ethyl acetate, drying, filtering and evaporating to obtain 10.7 g of the desired product.
  • Stage B: 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-0-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-fluoro-6-0-methyl-3-oxo-12,11-[oxycarbonyl[[(2R)-1-hydroxy-3-[(phenylmethyl)amino]-2-propyl]imino]-erythromycin
107 ml of methanol were added to 10.7 g of the product of Stage A and the mixture was stirred for 15 hours at ambient temperature. The methanol was evaporated off followed by drying to obtain 9.47 g of crude sought product which was purified by 2 successive chromatographies eluting with a methylene chloride/methanol/ammonium hydroxide mixture (96-4-0.4), then eluting with an ethyl acetate/triethylamine mixture to obtain 2.66 g of the desired product.
  • Stage C: 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-0-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-2-fluoro-6-0-methyl-3-oxo-12,11-[oxycarbonyl[(2R)-1-amino-3-hydroxy-2-propyl)imino]]-erythromycin
0.8 g of the product of Stage B, 8 ml of methanol, 315 mg of ammonium formate and 800 mg of palladium on carbon were mixed together and the reaction mixture was refluxed for 4 hours and 30 minutes under hydrogen. The reaction medium was allowed to return to ambient temperature and then was filtered. The filtrate was concentrated under reduced pressure to obtain 660 mg of product which was taken up in 20 ml of ethyl acetate followed by pouring into a 20% solution of ammonium hydroxide. The mixture was stirred followed by decanting and extracting with ethyl acetate, drying and filtering to obtain 660 mg of the desired product.
  • Stage D: 3aS,4R,7S,9R,10R,11R,13R,15R,15aR,18S)-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-hydroxymethyl)-11-methoxy-3a,7,9,11,13-15-hexamethyl-10-[[3,4,6-tridsexy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione
0.3795 g of the product of Stage C, 4 ml of ethanol and 62 μl of acetic acid were refluxed with stirring for 6 days and then was allowed to return to ambient temperature, followed by concentrating under reduced pressure. The residue was taken up in ethyl acetate and the solution was poured into a 20% solution of ammonium hydroxide. The mixture was stirred for 15 minutes followed by decanting, extracting with ethyl acetate, drying, filtering, rinsing and evaporating to obtain 0.304 g of product which was purified by chromatography on silica eluting with a chloroform/isopropanol/ammonium hydroxide mixture (90-10-0.4) to obtain 88 mg of the desired product.
Preparation 1 12-(oxycarbonylimidazol)-11-deoxy-10,11-didehydro-3-de[-2,6-dideoxy-3-C-methyl-3-0-methyl-α-L-ribohexopyranosyl)oxy]6-0-methyl-3-oxo-erythromycin 2′-acetoxy 2α-fluoro
  • Stage A: 11-deoxy 10,11-dedehydro-3-de[(2,6-dideoxy 3-0-methyl α-L-ribohexopyranosyl)oxy]6-0-methyl 3-oxoerythromycin.
A mixture of 8.722 g of 11-deoxy-10,11-didehydro-3-de[(2,6-dideoxy-3-0-methyl-α-L-ribohexopyranosyl)-oxy]-6-0-methyl-3-oxo-erythromycin (EP 596802) 2′-acetate and 350 ml of anhydrous methanol was stirred for 44 hours. The reaction medium was evaporated, taken up with methylene chloride and dried to obtain 8.794 g of the desired product.
  • Stage B: 11-deoxy-10,11-didehydro-3-de[(2,6-dideoxy-3-0-methyl-α-L-ribohexopyranosyl)-oxy]-6-0-methyl-3-oxo-erythromycin-2′-trimethylsilyloxy.
A mixture of 3.08 g of the product of Stage A, 340 mg of imidazole, 32 ml of anhydrous THF and 1.06 ml of hexamethyl-disilylazane was stirred at ambient temperature for 4 days. The reaction medium was then evaporated to dryness and the residue was taken up in a mixture of 60 ml of methylene chloride and 60 ml of a 0.5 M aqueous solution of sodium acid phosphate. The mixture was stirred for 15 minutes followed by decanting, extracting with is methylene chloride, drying and evaporating to dryness to obtain 3.345 g of the desired product.
  • Stage C: 11-deoxy 10,11-didehydro 3-de[(2,6-dideoxy 3-0-methyl α-L-ribohexopyranosyl)oxy]6-0-methyl 3-oxo erythromycin 2′-trimethylsilyloxy 2α-fluoro. p 1.24 ml of a sodium potassium terbutylate in 0.97M THF was added at −12° C., under an argon atmosphere, to a solution of 668 mg of 11-deoxy-10,11-didehydro-3-de[(2,6-dideoxy-3-0-methyl-α-L-ribohexopyranosyl)-oxy]-6-0-methyl-3-oxo-erythromycin-2′-trimethylsilyloxy and 6.7 ml of anhydrous THF. The mixture was stirred for 5 minutes and 378 mg of N-fluoro-dibenzenesulfonimide were added followed by stirring for 10 minutes at −12° C. The mixture was allowed to return to ambient temperature over 90 minutes. Isolation and purification operations were carried out to obtain 695 mg of the desired product.
  • Stage D: 11-deoxy-10,11-didehydro-3-de[(2,6-dideoxy-3-C-methyl-3-0-methyl-α-L-ribohexopyranosyl)-oxy]-6-0-methyl-3-oxo-erythromycin-2α-fluoro.
A mixture of 5.476 g of the product of Stage c, 50 ml of THF and 11.2 ml of 1M tetrabutylammonium fluoride in THF was stirred for 3 hours 30 minutes and the solvent was evaporated off. 37 ml of ethyl acetate, 37 ml of water and 7.5 ml of ammonium hydroxide at 20% were added and the mixture was stirred for 10 minutes followed by decanting, extraction with ethyl acetate, drying and filtering. The filtrate was concentrated to dryness and the product was chromatographed on silica eluting with an ammoniated CH2Cl2—MeOH mixture 99-1, then 98-2, 97-3, 96-4, 95-5 to obtain 2.452 g of the desired product.
  • Stage E: 11-deoxy 10,11-didehydro 3-de[(2,6-dideoxy 3-C-methyl-3-O-methyl-α-L-ribohexopyrasonyl)oxy]6-O-methyl 3-oxo erythromycin 2′-acetoxy 2α-fluoro.
1.02 g of the product of Stage D, 10 ml of methylene chloride and 241 μl of acetic anhydride were stirred for 3 hours followed by evaporation. Then, 10 ml of water and 10 ml of ethyl acetate were added and the reaction medium stood for 1 hour at ambient temperature with stirring, followed by decanting, drying and evaporating to obtain 1.01 g of the desired product.
  • Stage F: 12-(oxycarbonylimidazol)-11-deoxy-10,11-didehydro-3-de[(2,6-dideoxy-3-C-methyl-3-0-methyl-α-L-ribohexopyranosyl)-oxy]-6-0-methyl-3-oxo-erythromycin-2′-acetoxy-2α-fluoro.
0.388 g of carbonyldiimidazole and 24 μl of DBU were added at 0° C. to a solution of 1.01 g of the product of Stage E and 10 ml of anhydrous THF and the mixture was stirred at 0° C. for 19 hours. The THF was evaporated off and 10 ml of water and 10 ml of ethyl acetate were added. The reaction mixture was stirred for 10 minutes followed by extracting, drying and evaporating to obtain 0.902 g of the crude sought product which was chromatographed eluting with an ethyl acetate-triethylamine mixture 96-4 to obtain 0.573 g of the desired product.
EXAMPLE 3 (3aS,4R,7S,9R,10R,11R,13R,15R,15aR,18S)-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-[[[(4-quinoleinyl)carbonyl]oxy]methyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione
  • Stage A: (3aS,4R,7S,9R,10R,11R,13R,15R,15aR,18S)-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-(hydroxymethyl)-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione
299 mg of the product of Example 2, 3 ml of ethyl acetate and 46 μl of acetic anhydride were stirred at ambient temperature for 20 hours and then was poured into a 20% saturated solution of ammonium hydroxide followed by stirring for 20 minutes, decanting and extracting with ethyl acetate, drying, filtering and evaporating to obtain 0.3296 g of the desired product.
  • Stage B:(3aS,4R,7S,9R,10R,11R,13R,15R,15aR,18S)-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-[[[(4-quinoleinyl)carbonyl]oxy]methyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione
A mixture of 180 mg of the product of Stage A, 6 ml of methylene chloride, 137 μl of TEA, 0.142 g of acid chloride and 33.2 mg of DMAP was refluxed for 5 hours 30 minutes and the reaction mixture was then poured into a 10% aqueous solution of ammonium hydroxide followed by decanting. The organic phase was washed with a saturated aqueous solution of sodium chloride and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried, filtered and evaporated to obtain 0.23 g of the crude sought product which was purified by chromatography on silica eluting with a chloroform, isopropyl alcohol, ammonium hydroxide mixture 96-4-0,1%.
  • Stage C: (3aS,4R,7S,9R,10R,11R,13R,15R,15aR,18S)-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-[[[(4-quinoleinyl)carbonyl]oxy]methyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione.
A mixture of 0.135 g of the product of Stage B and 2 ml of methanol was stirred for 24 hours followed by evaporating to dryness. The residue was taken up in ethyl acetate and 20 ml of 10% ammonium hydroxide were added. The mixture was stirred for 10 minutes followed by decanting, extracting with ethyl acetate, drying, filtering and evaporating. The residue was taken up in ether, filtered and dried to obtain the desired product with a rf=0.40 (CHCl3, MeOH, NH4OH=96-4-0.4, and with a mass spectrum MH+=683+.
Example of Pharmaceutical Composition
Tablets containing 150 mg of the Product of Example 1 and sufficient excipient of starch, talc, magnesium stearate for 1 g tablets.
PHARMACOLOGICAL STUDY
Method of Dilutions in Liquid Medium
A series of tubes were prepared in which the same quantity of nutritive sterile medium was distributed. Increasing quantities of the product to be studied were distributed into each tube and then each tube was seeded with a bacterial strain. After incubation for twenty-four hours in an oven at 37° C., the growth inhibition was evaluated by transillumination, which allowed the minimal inhibitory concentrations (M.I.C.) to be determined, expressed in micrograms/ml. The following results were obtained: (reading after 24 hours)
TABLE 1
Example Example
GRAM* bacterial strains 1 3
S. aureus 011UC4 0.150 0.040
S. aureus 011UC4 + 50% serum 0.040 0.040
S. aureus 011GO251 0.600 0.040
S. epidermidis 012GO111 0.300 0.150
S. pyogenes 02A1UC1 0.040 #0.02
S. agalactine 02B1HT1 #0.02 0.02
S. foccolis 02D2UC1 0.040 0.02
S. faccium 02D3HT1 #0.02 0.02
Streptococcus gr. G02GOGR5 0.040 0.02
S. mitis 02MitCB1 0.040 0.02
S. agalactine 02B1S11c 1.200 0.02
S. pneumoriae 032UC1 0.080 0.02
S. pneumoriae 030GR20 #0.02 0.02
Moreover, the product of Example 1 showed a useful activity on the following Gram bacterial strains: Haemophillus Influenzae 351HT3, 351CB12 and 351CA1.
Various modifications of the products of the invention may be made without departing from the spirit or scope thereof and it is to be understood that the invention is intended to be limited only as defined in the appended claims.

Claims (12)

1. A compound selected from the group consisting of the formula
Figure USRE039743-20070724-C00019
wherein A is nitrogen or N→O, R1 and R2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 18 carbon atoms, R is —(CH2)mOB, Hal is halogen, m and n are individually an integer from 1 to 8, B is hydrogen or
Figure USRE039743-20070724-C00020
or —(CH2)n—Ar, Ar is mono- or polycyclic aryl or heteroaryl, Z is hydrogen or acyl of an organic carboxylic acid of up to 18 carbon atoms and its non-toxic, pharmaceutically acceptable acid addition salts.
2. A compound of claim 1 wherein R1 and R2 are hydrogen.
3. A compound of claim 1 wherein A is nitrogen.
4. A compound of claim 1 wherein Hal is fluorine.
5. A compound of claim 1 wherein R is —CH2OH.
6. A compound of claim 1 which is (3aS, 4R*, 7S*, 9R*, 10R*, 11R*, 13R*, 15R*, 15aR*, 18S*)-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-(hydroxymethyl)-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-14,1-(nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione.
7. An antibiotic composition comprising an antibiotically effective amount of a compound of claim 1 and an inert pharmaceutical carrier.
8. An antibiotic composition comprising an antibiotically effective amount of a compound of claim 6 and an inert pharmaceutical carrier.
9. A method of treating bacterial infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antibiotically effective amount of a compound of claim 1.
10. A method of treating bacterial infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antibiotically effective amount of a compound of claim 6.
11. A process for the preparation of a compound of claim 1 comprising reacting a compound of the formula
Figure USRE039743-20070724-C00021
wherein Hal is halogen and OM is a protected hydroxyl with a compound of the formula
Figure USRE039743-20070724-C00022
wherein m is an integer from 1 to 8 to obtain a compound of the formula
Figure USRE039743-20070724-C00023
deprotecting the 2′-hydroxyl to obtain a compound of the formula
Figure USRE039743-20070724-C00024
reacting the latter with a debenzylating agent to obtain a compound of the formula
Figure USRE039743-20070724-C00025
reacting the latter with a cyclization agent to form a compound of the formula
Figure USRE039743-20070724-C00026
corresponding to a compound of Formula I of claim 1 wherein R is —(CH2)m—OH and optionally subjecting the latter to an aralkylating or acylating agent to obtain a compound of formula I of claim 1 wherein B is —(CH2)n—Ar or
Figure USRE039743-20070724-C00027
12. A compound selected from the group consisting of
Figure USRE039743-20070724-C00028
where the substituents are defined as in claim 11wherein m, R1 , R 2 , and Hal are as defined in claim 1 ; and OM is a protected hydroxyl.
US10/302,324 1998-10-15 2002-11-21 2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use Expired - Lifetime USRE39743E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/302,324 USRE39743E1 (en) 1998-10-15 2002-11-21 2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9812937A FR2784682B1 (en) 1998-10-15 1998-10-15 NOVEL 2-HALOGEN DERIVATIVES OF 5-0-DESOSAMINYLERYTHRONOLIDE A, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
US09/416,022 US6352983B1 (en) 1998-10-15 1999-10-08 2-halogenated derivatives of 5-0 desosaminyl-erythronolide A, their preparation process and their antibiotic use
US10/302,324 USRE39743E1 (en) 1998-10-15 2002-11-21 2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/416,022 Reissue US6352983B1 (en) 1998-10-15 1999-10-08 2-halogenated derivatives of 5-0 desosaminyl-erythronolide A, their preparation process and their antibiotic use

Publications (1)

Publication Number Publication Date
USRE39743E1 true USRE39743E1 (en) 2007-07-24

Family

ID=26234600

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/302,324 Expired - Lifetime USRE39743E1 (en) 1998-10-15 2002-11-21 2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use

Country Status (1)

Country Link
US (1) USRE39743E1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019010447A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. Compositions for parenteral administration of therapeutic agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487411A1 (en) * 1990-11-21 1992-05-27 Roussel Uclaf Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments
FR2742757A1 (en) * 1995-12-22 1997-06-27 Roussel Uclaf New erythromycin derivatives
WO1999021871A1 (en) * 1997-10-29 1999-05-06 Abbott Laboratories 2-halo-6-o-substituted ketolide derivatives
US6124269A (en) * 1997-10-29 2000-09-26 Abbott Laboratories 2-Halo-6-O-substituted ketolide derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487411A1 (en) * 1990-11-21 1992-05-27 Roussel Uclaf Erythromycin derivatives, their preparation, intermediates obtained and their application as medicaments
FR2742757A1 (en) * 1995-12-22 1997-06-27 Roussel Uclaf New erythromycin derivatives
WO1999021871A1 (en) * 1997-10-29 1999-05-06 Abbott Laboratories 2-halo-6-o-substituted ketolide derivatives
US6124269A (en) * 1997-10-29 2000-09-26 Abbott Laboratories 2-Halo-6-O-substituted ketolide derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019010447A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. Compositions for parenteral administration of therapeutic agents

Similar Documents

Publication Publication Date Title
AU670329B2 (en) New derivatives of erythromycin, their preparation process, their use as medicaments
US6096714A (en) Erythromycin derivatives, method for preparing same, and use thereof as drugs
US6440941B1 (en) Derivatives of erythromycin, their preparation process and their use as medicaments
US6455505B2 (en) Derivatives . . . use as medicaments
AU697876B2 (en) New erythromycin derivatives, their preparation process and their use as medicaments
US6313101B1 (en) Derivatives of erythromycin, their preparation process and their use as medicaments
CA2301643A1 (en) 6,9-bridged erythromycin derivatives
US6352983B1 (en) 2-halogenated derivatives of 5-0 desosaminyl-erythronolide A, their preparation process and their antibiotic use
US6433151B1 (en) Erythromycin derivatives, a process for their preparation and their use as medicaments
USRE39743E1 (en) 2-halogenated derivatives of 5-0 desosaminyl-erythronolide a, their preparation process and their antibiotic use
JP5188520B2 (en) Novel erythromycin derivative, production method and pharmaceutical use
AP997A (en) Novel erythromycin derivatives, method for preparing them and their use as medicine.
IL108622A (en) 9-(1-substituted piperdine-3-yloxime) derivatives of 3-De(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy-6-O-methyl-3-oxo erythromycin their preparation process and their use as medicaments
USRE38520E1 (en) Erythromycin derivatives, method for preparing same, and use thereof as drugs
US6706692B1 (en) 6-deoxy erythromycin derivatives, method for preparing same and use as medicines

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12